In this episode, Ben Hopkins sits down with longevity scientist Professor Matt Kaeberlein to unpack the biggest questions in aging, health span, and the science of living longer.They cover the promise and pitfalls of biological age clocks, why resveratrol failed to live up to the hype, how to think about aging as entropy and resilience, and which interventions actually look promising today. Matt also explains where lifestyle, hormones, and medications like rapamycin, SGLT2 inhibitors, GLP-1 agonists, and more fit into a practical longevity strategy.If you’re interested in evidence-based longevity, proactive health, and the future of aging research, this conversation is packed with insights.00:00 Intro00:37 Are biological age clocks a breakthrough or a gimmick?06:04 What is aging, really?11:25 Resveratrol: signal or noise?21:58 The biggest proven levers for health and lifespan27:25 SGLT2 inhibitors, GLP-1s, and proactive medicine38:28 Testosterone, hormones, and aging51:01 Why rapamycin has been so misunderstood55:13 Compound bets: what’s most promising?60:50 What surprised Matt most in longevity science?63:58 The Dog Aging Project and longevity research in dogsLearn more about Matt’s work on the Dog Aging Project and Dog Aging Institute, and check out his podcast and research updates for more on the science of longevity.If you enjoyed this conversation, please like, subscribe, and share it with someone who would benefit from learning more about women's metabolic health.-------------------------------------------------------------------------------------------------------------------------Exploring the benefits of red and infra light therapy? Our community receive 10% off via this linkWant to watch this on video? Subscribe on YouTubeInstagram @degreesofhealthDisclaimer Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related